Illumina, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Vanguard Total Stock Market Index Fund ETF trades at $368. Which is the better fit depends on your goals.
| ILMN | VTI | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | — |
52-Week High | $194.33 | $374.36 |
52-Week Low | $91.00 | $305.74 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
VTI trades at $366.25, down 0.21% on the day, with a bearish technical signal from moving averages. The ETF provides diversified exposure to the entire U.S. stock market with over 3,500 holdings and an ultra-low 0.03% expense ratio. Recent news highlights its appeal for long-term investors seeking broad market coverage and historical resilience during market downturns.
The outlook remains positive for buy-and-hold investors given VTI's diversification benefits and cost efficiency. Key risks include broader market volatility and sector concentration in technology. Wall Street sentiment is generally favorable for long-term wealth building, though short-term technical indicators suggest caution.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →